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Abstract
Background Melanoma is a malignancy that stems from melanocytes and is defined as the most dangerous skin malignancy in
terms of metastasis and mortality rates. CXC motif chemokine 10 (CXCL10), also known as interferon gamma-induced protein-
10 (IP-10), is a small cytokine-like protein secreted by a wide variety of cell types. CXCL10 is a ligand of the CXC chemokine
receptor-3 (CXCR3) and is predominantly expressed by T helper cells (Th cells), cytotoxic T lymphocytes (CTLs), dendritic
cells, macrophages, natural killer cells (NKs), as well as some epithelial and cancer cells. Similar to other chemokines, CXCL10
plays a role in immunomodulation, inflammation, hematopoiesis, chemotaxis and leukocyte trafficking.
Conclusions Recent studies indicate that the CXCL10/CXCR3 axis may act as a double-edged sword in terms of pro- and anti-
cancer activities in a variety of tissues and cells, especially in melanoma cells and their microenvironments. Most of these
activities arise from the CXCR3 splice variants CXCR3-A, CXCR3-B and CXCR3-Alt. In this review, we discuss the pro-
and anti-cancer properties of CXCL10 in various types of tissues and cells, particularly melanoma cells, including its potential as
a therapeutic target.
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1 Introduction
Chemokines comprise a large family of low molecular weight
(8–15 kDa) polypeptides. Based on the position of conserved
cysteine residues, chemokines are classified into four groups:
C, CC, CXC and CX3C [1, 2].More than 44 chemokine genes
have been identified within the human genome, and they exert
their biological functions via interactions with subunits of
seven-transmembrane G protein-coupled receptors (GPCRs).
CXCL10, also known as IP-10, is one member of the
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chemokine family and represents a so-called C-x-C motif li-
gand (CXCL); the Cs of C-x-C refer to two N-terminal cyste-
ines separated by one random amino acid (x) [3]. The
CXCL10 encoding gene is located on chromosome 4q21
[4]. In accordance with the biological functions of
chemokines, CXCL10 is highly expressed in a wide range
of human disorders affecting leukocyte trafficking, adaptive
immunity, angiogenesis, inflammation and hematopoiesis [5].
Under pro-inflammatory conditions, CXCL10 is secreted in
response to interferon-gamma (IFN-γ) by various cell types,
including leukocytes, monocytes, activated neutrophils, eo-
sinophils, epithelial cells, endothelial cells, stromal cells and
keratinocytes [4, 6, 7]. CXC chemokine receptor-3 (CXCR3)
is an interferon-inducible chemokine receptor, GPCR, which
is known as GPR9 or CD183, and plays a crucial role in
immunity and inflammation. It is predominantly expressed
by a variety of immune cells, including T helper cells (Th
cells, also known as CD4+ T cells), cytotoxic T lymphocytes
(CTLs, also known as CD8+T cells), dendritic cells, macro-
phages, natural killer (NK) cells, some epithelial and cancer-
ous cells, and infiltrating and intraepithelial lymphocytes in
inflammatory conditions and secondary lymphoid organs, re-
spectively [8–11].
Over the past few decades, it has become eveident that
CXCL10 may play a critical role in both tumor inhibition
and promotion [9, 12]. The CXC chemokine subgroup can
be categorized into two major groups depending on whether
or not an ELR (Glu-Leu-Arg) motif is present. Chemokines
with this motif induce neutrophil migration, whereas those
without it allow lymphocytes to migrate and attenuate angio-
genesis [13, 14]. CXCL9, 10 and 11 are ELR-negative CXC
chemokines secreted by monocytes, endothelial cells, fibro-
blasts and cancer cells and can ameliorate angiogenesis and
tumor growth in various cancers, such as melanoma [15],
colon, lung [16], prostate [17], gastric [18], cervical [19] and
brain [20] cancers. The CXCl9, 10, 11/CXCR3 axis plays a
critical role in regulating immune responses through the re-
cruitment of various immune cells, including CTLs, NK cells
and macrophages [21]. This axis induces Th1 cell migration
and inhibits Th2 cell migration. CXC9 is expressed through
induction by IFN-γ, but not IFN-α/β, and regulates lympho-
cyte infiltration to the tumor microenvironment, resulting in
inhibition of tumor progression [22]. CXCL10 expression is
induced by IFN-α/β, TNF-α and NF-κB [23–25], whereas
CXCL11 is induced by INF-γ, -α and -β and has the highest
binding affinity to CXCR3, followed by CXCL10 and
CXCL9. CXCL11 binds to CXCR3 through a domain differ-
ent from that of the two other ligands [26]. Overexpression of
CXCL10 and CXCR3 has been found to be associated with
advanced tumor stages in melanoma [27], lymphoma [28],
brain cancer [29], hepatocellular carcinoma (HCC) [30], mul-
tiple myeloma [31], ovarian carcinoma [32], lung adenocarci-
noma [33], breast cancer [34, 35], papillary thyroid carcinoma
(PTC) [36], osteosarcoma [37] and pancreatic cancer (PCC)
[38].
Melanomas arise from pigment-producing cells known as
melanocytes, which are predominantly located in the skin, but
can also be seen in other areas, including iris, hair follicles and
mucosa [39–41]. Histopathologically, melanomas can be cat-
egorized into skin melanoma (also known as cutaneous mel-
anoma), naevoid melanoma, spitzoidmelanoma, desmoplastic
melanoma, ocular/choroidal melanoma, mucosal melanoma,
acral melanoma and amelanotic melanoma [42]. Cutaneous
melanoma is the most common and well-defined clinical var-
iant and its incidence is rising annually [43, 44]. It is the most
aggressive and deadliest form of cutaneous malignancies due
to its highly metastatic nature [45]. Exposure to ultraviolet
(UV) light, particularly from the sun, causes genetic alter-
ations that are the major risk factors for its occurrence [46].
Based on the International Agency for Research on Cancer
(IARC) data, the number of new melanoma cases in 2018
was 287,723, with 60,712 deaths worldwide [47].
Different histopathological variants of melanoma exhibit
distinct 5-year survival rates, i.e., the 5-year survival rate of
cutaneous melanoma (82∙9–83.6%) is relatively higher than
that of ocular/choroidal melanoma (65.0–75.0%). Moreover,
the 5-year survival rate of cutaneous melanoma varies be-
tween countries, i.e., in Bulgaria (47·0–52.0%) it is markedly
less than in the UK (Northern Ireland; 88·1–92%) [48]. These
striking differences appear to be correlated with variations in
early diagnosis programs, the accuracy of diagnostic strate-
gies, the accessibility to healthcare systems as well as screen-
ing plans to prevent melanoma [42, 48].
Melanoma invasion, proliferation and metastasis, as well as
its mitotic index, can be remarkably reduced by leukocyte
trafficking, angiostatic and immunomodulatory properties of
CXCL10 [15]. Conversely, it has been found that paracrine
interactions between tumor and stromal cells mediated by on-
cogenic CXCL10 can lead to leukocyte trafficking and angio-
genesis and, consequently, metastatic recurrence [27].
These are just a few examples of the anti- and pro-
tumorigenic properties of CXCL10. We decided to outline
the anti- and pro-tumorigenic properties of CXCL10 in vari-
ous types of cancer, especially melanoma, as well as several
CXCL10-based therapeutic approaches, alone or in combina-
tion, to attenuate/inhibit the angiogenesis, metastasis and pro-
liferation of melanoma cells.
2 CXCL10 and its receptor CXCR3
CXCL10 is a small (10 kDa) cytokine-like protein that is
induced by IFN-γ and IFN-α/β [23]. CXCL10 induction is
also weakly mediated by TNF-α [49]. To emphasize its im-
portance, Ming-Fang et al. found that CXCL10 deficient mice
exhibited a higher mortality rate after primary dengue virus
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(DENV) infection compared to wild-type mice [50]. The che-
motactic activity of CXCL10 depends on the presence of
CXCR3 on the surface of specific cells, primarily Th1 cells,
CTLs, NK cells and natural killer T cells (NKT cells) [8–11].
C o n s e q u e n t l y , CXCL 1 0 i s i n v o l v e d i n t h e
immunomodulation of both innate and adaptive immunity. It
attracts and promotes the infiltration of immune cells to dam-
aged or inflamed discrete/continuous tissues, and contributes
to anticancer cytotoxic activity or tumorigenesis (i.e., prolif-
eration, migration, invasion and metastasis) [9, 27, 36].
Recent studies have indicated that CXCL10 is associated with
a variety of disorders, including various cancers. CXCL10
exerts its biological functions via CXCR3 through the induc-
tion of paracrine and/or autocrine signaling, and it has been
identified as an important prognostic indicator for various dis-
eases [7, 9, 51]. The amino acid sequence of CXCL10 shows
significant homology to proteins having chemotactic (e.g.
platelet factor 4, β-thromboglobulin) and mitogenic (e.g. con-
nective tissue activation peptide HI) activities, which are as-
sociated with inflammation and cell proliferation [4, 52]. The
pleiotropic anti- and pro-tumorigenic properties of CXCL10
are related to the expression of CXCR3 splice variants in
different tissues/cells [51]. The CXCR3 transcript can gener-
ate three potential alternative splice variants exhibiting cell-
type specific expression patterns, including CXCR3-A,
CXCR3-B and CXCR3-Alt, which contribute to the activation
of different signaling pathways [53]. CXCL10 activates the
CXCR3-Avariant, the main and traditional isoform present in
most cell types, leading to intracellular calcium influx induc-
tion, DNA synthesis, chemotaxis and proliferation [54].
Overexpression of CXCR3-A has been found to contribute
to the invasion and metastasis of gastric cancer and lung ade-
nocarcinoma cells [33, 55]. In addition, CXCL10 has been
found to exhibit full agonistic activity for Gαi activation and
extracellular signal-regulated kinase (ERK) 1/2 phosphoryla-
tion, and partial agonistic activity for β-arrestin recruitment of
splice variant CXCR3-B. Additionally, CXCR3-B has been
found to be expressed on tumorous endothelial cells, but to
be down-regulated in some malignancies such as human
breast cancer and melanoma. CXCR3-B may be involved in
suppressing cellular growth and/or proliferation as well as in
inhibiting apoptosis and angiogenesis through interactions
with CXCL10 [34, 56, 57]. Although the biological properties
of CXCR3-Alt require further investigation, CXCL10 has
been found to induce its partial activation [11].
All three CXCR3 variants are expressed on T cells, and in
terms of immune cell migration, they exhibit an equal effec-
tiveness in activating Th1 cells, CTLs and NK cells [58, 59].
Generally, in a paracrine-dependent manner, the CXCL10/
CXCR3 axis plays an important role in the anti-tumor effects
of Th1 cells, CTLs, NK cells and NKT cells. However, in an
autocrine-dependent manner, CXCL10/CXCR3 signaling has
been found to increase the proliferation, angiogenesis and
metastasis of tumor cells [60]. Altogether, the paradoxical
roles of CXCL10 in its anti- and pro-tumorigenic effects seem
to depend on the receptor subtypes expressed and/or the cell
types concerned, but the underlying mechanisms await to be
fully elucidated. Among the various malignancies involved,
specific attention has recently been paid to the role of CXCR3
in melanoma development, and several studies have con-
firmed correlations between CXCR3 expression and T cell
infiltration in cancer (melanoma) prognosis (Fig. 1).
3 Tumorigenic properties of CXCL10
One of the reasons why immune responses fail to control
cancer development may be related to specific chemokine
and cytokine network expression patterns [61]. Tumor micro-
environmental cells, like stroma cells, are capable of releasing
pro-inflammatory mediators, i.e., chemokines, leading to the
recruitment of inflammatory and innate/adaptive immune
cells from peripheral blood [62, 63]. In addition, immune
and inflammatory responses may have dual effects, one of
them being supporting tumor progression with inflammatory
responses, the other being suppressing tumor growth with the
aid of adaptive immune responses through tumor-specific an-
tigens [64, 65]. Recent studies have indicated that the
CXCL10/CXCR3 axis may be associated with the
promotion/induction of various types of cancer, including
breast cancer [34, 35], PCC [38], HCC [30, 66], melanoma
[27], lymphoma [28], brain cancer [29], PTC [36], lung ade-
nocarcinoma [33] and osteosarcoma [37].
According to what has been noted above, the autocrine-
dependent mode of action of the CXCL10/CXCR3 axis im-
plicates that some tumorous cells express both CXCL10 and
CXCR3 for their growth, progression andmetastasis. Such co-
expression has been encountered in some human breast cancer
cells [34, 35], colon cancer cells [67], basal cell carcinoma
cells [7], lung adenocarcinoma cells [33] and nasal natural
killer/T cell lymphoma cells [28]. Interestingly, Datta et al.
reported that an activated form of Ras, Ha-Ras (12 V), plays
a critical role in the proliferation of MDA-MB-435 and MCF-
7 breast cancer cells through modulation of CXCL10
(overexpression) and CXCR3-B (down-regulation). Ras-
induced overexpression of CXCL10was found to bemediated
through the Raf and phosphatidylinositol 3-kinase (PI3-
kinase) signaling pathways [34]. Besides, it was shown that
CXCL10, in a hormone-independent manner, promoted the
progression and metastasis of human breast cancer cells via
the induction of various signaling pathways affectingβ-caten-
in, MAP kinase phosphatase 1 (MKP-1) and matrix metallo-
proteinase 1 (MMP-1) expression [35]. Additionally, it was
found that CXCL10 up-regulates the expression of the pro-
tumoral CXCR3-A splice variant, the phosphorylation of
ERK1/2, the enhancement of migrat ion of lung
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adenocarcinoma cells (mucinous H2228 cells) and, finally, the
function of the CXCL10/CXCR3-A axis as an autocrine loop
[33].
Up-regulated expression of CXCL10 has been found to
correlate with a poor prognosis and a decrease in the median
overall survival in PCC, osteosarcoma and melanoma patients
[27, 38]. Moreover, in PCCs, the paracrine-dependent mode
of action of CXCL10 has been found to be associated with the
intra-tumoral presence of regulatory T cells (Tregs), leading to
immunosuppression and subsequent tumor-promoting effects
[38]. Notwithstanding this issue, evidence suggests that
CXCL10 accelerates the invasiveness, epithelial to mesenchy-
mal transition (EMT) and/or metastasis (via activating MMP-
2 expression) [30] and recurrence (in a CXCR3/c-Myc depen-
dent manner) in HCC [66].
In the brain, CXCL10 plays a role in the recruitment and
homing of glial cells expressing CXCR3 during embryonic
development [29]. In addition, CXCL10 may be involved in
glioma development [68]. In support of this notion,Maru et al.
reported that CXCL10 induces glioma proliferation in an
ERK1/2-dependent manner [69]. As described above, the
paracrine and autocrine modes of action of the CXCL10/
CXCR3 axis may play important roles in melanoma develop-
ment. Paracrine CXCL10/CXCR3 signaling mediates interac-
tions between tumor and stromal cells leading to leukocyte
trafficking, angiogenesis and tumorigenesis [70], whereas
the autocrine CXCL10/CXCR3 axis has been shown to be
critical in enhancing metastatic recurrence and melanoma pro-
gression [27]. Together, these data indicate a wide-range of
tumorigenic properties of CXCL10, particularly through an
autocrine loop, turning it into a putative therapeutic target
(Table 1).
4 Anti-cancer properties of CXCL10
CXCL10 is a chemokine that beyond its chemotactic property,
has been shown to possess anti-tumor effects (Table 2). Recent
Fig. 1 Suggested roles of CXCR3 and its ligands in melanoma
development. CXCR3 is thought to play at least two essential roles in
melanoma development. CXCR3 onmelanoma cells may not only induce
metastasis from the primary site through endothelial invasion, but also
CXCL9/10 production by the tumor cells. At the same time, melanoma
cells may induce Type 1 interferon expression by APCs, such as
plasmacytoid dendritic cells (pDCs), to up-regulate CXCL10, which re-
sults in the recruitment of T cells and NK cells expressing CXCR3 from
the blood stream to the tumor site. At the tumor site, T cells and NK cells
generate IFN-γ, which induces the expression of CXCL9/10/11 in
keratinocytes, APCs and other skin cells in order to recruit adaptive im-
mune cells with anti-tumor activities to kill the tumor cells
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studies have elucidated the effects of CXCL10 and CXCR3
on melanoma development, and their use in predicting early
metastastic recurrence, recruiting immune cells, inhibiting
proliferation/tumor growth, reducing invasion, inhibiting an-
giogenesis and improving overall survival rates [15, 27].
Moreover, in advanced stages of melanoma development, it
has been found that CXCR3-B is down-regulated in most
patients and, as noted earlier, that CXCR3-B plays a role in
inhibiting angiogenesis, apoptosis and proliferation [57].
Overall, most of the anti-tumorigenic activities of the
CXCL10/CXCR3 axis are associated with a paracrine-
dependent mode of action, whereas its pro-tumorigenic activ-
ities are mostly associated with an autocrine-dependent mode
of action [27].
The paradoxes in CXCL10/CXCR3 properties can at least
partially be explained by the heterogeneity and multifactorial
manifestations of cancers, and by the occurrence of different
genetic and epigenetic alterations [71]. Most of the anti-
tumorigenic activities of CXCL10 occur in a paracrine-
dependent manner [11] and chemotaxis, immunomodulation,
apoptosis induction [19], proliferation suppression [17] and
angiogenesis/neovascularization inhibition [16, 20] are
among the anti-tumorigenic effects of CXCL10. Besides, dif-
ferences in CXCR3 subtype expression levels have been as-
sociated with the proliferation, metastasis and invasiveness of
tumor cells [55]. As mentioned earlier, CXCL10 attracts
CXCR3+ immune cells to its secretion zone. In colorectal
cancer, for example, secretion of active CXCL10 has been
found to be associated with infiltration of CXCR3+CD8+ T
cells and IFN-γ+CD4+ Th cells into the tumor site, conse-
quently potentiating anti-tumor activity through Granzyme B
and IFN-γ production from CD8+ T cells and CD4+ Th cells,
respectively [72]. Moreover, it has been found that the
CXCL10/CXCR3 axis can polarize Th1 cells and that subse-
quently, through IFN-γ secretion, these cells can induce acti-
vation of CD8+ T cells, NK cells and NKT cells [15, 21].
Additionally, it has been found that CXCL10-deficient mice
show an impaired generation of Ag-specific effector T cells
and an impaired trafficking of, particularly, Th1 cells that play
pivotal roles in recruiting activated T cells to the secretion
zones [73]. Based on both adaptive and innate immunity ef-
fects, improvement of an anti-tumor response is considered to
be a multifaceted and harmonized phenomenon. Activated T
cells must move towards the tumor microenvironment during
the effector phase of the anti-tumor response. This process
depends on the indigenous generation of particular
chemokines such as CXCL10 and CXCL9 [11].
As mentioned above, the angiostatic property of CXCL10
is based on absence of the ELR motif [13]. CXCL10 has been
reported to exhibit an angiostatic property and to attract T
lymphocytes in gastric cancer [18] and Li et al. found that
CXCL10 is a well-tolerated angiogenesis inhibitor in lung
and colon carcinomas [16]. CXCL10 also exerted a tumor
neovascularization-inhibitory property in an in vivo model
of glioma [20]. Zhao et al. found that CXCL10 inhibits angio-
genesis, induces apoptosis, reduces vessel density and pre-
vents entry into the S phase of the cell cycle in cervical cancer
cells [19]. In prostate cancer LNCaP cells, CXCL10 has been
found to exhibit inhibitory effects on their proliferation and to
decrease PSA production through CXCR3 up-regulation [17].
Furthermore, Rentoft et al. found that higher CXCL10 expres-
sion levels are associated with less effective responses to ra-
diotherapy in tongue cancer patients [74]. On the other hand,
high CXCL10 expression levels have been found to correlate
with an approximately double survival rate, as well as a
tumor-suppressive function through the recruitment of
Table 1 Tumorigenic properties of CXCL10
Cancer Tumorigenesis effect(s) Model Cell line(s) Ref.
Breast Induces Ras, Raf and PI3-kinase In vitro MDA-MB-435 and MCF-7 [34]
Pancreatic Immunosuppressive and tumor-promoting effects In vitro Panc-1, MiaPaCa-2, Capan-1, Capan-2,
Hs766T and MRC5
[38]
Hepatocellular Induces migration, invasion and metastasis In vitro, In vivo HepG2, MHCC97H, SMMC-7721 and MHCC97L [30]
Melanoma Induces tumor growth, motility and metastasis In vivo, In vitro B16F1 [27]
Lymphoma Induces invasion in nasal NK/T-cell lymphoma
through an autocrine mechanism
In vitro SNK-6 and SNT-8 [28]
Hepatocellular Induces c-Myc expression Human HepG2 [66]
Brain Induces recruitment and homing of glial cells
during embryogenesis
In vitro NG-108 [29]
Papillary thyroid Induces proliferation and invasion Human Thyroid follicular cells [36]
Lung Up-regulates CXCR3-A expression, Erk1/2
phosphorylation and induces cell migration
Human H2228 [33]
Breast Induces metastasis (β-catenin, MKP-1 and
MMP-1 up-regulation)
Human MCF-7 [35]
Bone (osteosarcoma) – Human – [37]
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tumor-infiltrating lymphocytes (TILs) in human ovarian can-
cer [75]. Apart from this, it has been shown that recombinant
CXCL10 markedly enhances the proliferation and expansion
of CXCL10-recruited TILs in response to tumor-Ag in a xe-
nograft model of breast cancer [60].
As described above, CXCL10 is a potent anti-cancer che-
mokine exhibiting a wide range of activities. However, the use
of a single chemokine in cancer therapy may, due to the vast
heterogeneity of cancer, not be very efficacious, whereas
using CXCL10 in combination with other therapeutic strate-
gies may be beneficial. It has e.g. been reported that combi-
nations of CXCL10 therapy and radiotherapy may improve
therapeutic efficacies in xenograft models of cervical cancer
[19]. Moreover, combinations of CXCL10 and cisplatin, a
commonly used chemotherapeutic agent in solid tumors, have
been found to enhance anti-cancer activities [16]. Also, as
mentioned above, high CXCL10 expression has been found
to be related to incomplete radiotherapy responses in tongue
cancer [74].
5 CXCL10 and melanoma therapy
Diverse clinical presentations and genotypes (arising from
different genetic and/or epigenetic alterations) of melanomas
accentuate that these melanocyte-derived malignancies are
heterogeneous in nature [77]. Current therapeutic strategies,
including surgical resection, chemotherapy, bio-chemothera-
py, radiation therapy, immunotherapy, targeted therapy and
novel treatment modalities that are being tested in clinical
trials (e.g. vaccine therapy), can be used alone or in combina-
tion [45]. As a matter of fact, however, melanomas are capable
of resisting various therapeutic strategies through alterations
in the tumor microenvironment, apoptosis inhibition, targeting
BRAF and MEK for blocking MAPK and increasing CD4+
and CD8+ lymphocytes, respectively. Utilizing a proper ther-
apeutic strategy is, therefore, challenging, which is one of the
main reasons for the > 60,000 deaths frommelanoma annually
[47, 78].
Application of immune checkpoint inhibitors, which im-
proves anti-cancer immunity, is a favorable treatment option for
different types of “immunogenic” cancers, including melanomas
[79]. In this regard, functions of effector Tcells are attenuated by
inhibitory receptors expressed on the surface of Treg cells, i.e.,
programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) [79]. By expressing CTLA-4,
FOXp3+ Treg cells counter immunostimulatory functions of
the B7–1 andB7–2 (CD80/CD86) receptors which are expressed
on antigen presenting cells [80]. Effector T cell responses are
confined by signaling through the CTLA-4/B7–1 and B7–2
pathways [80]. Anti CTLA-4-based therapywas for the first time
used by James Allison and his group [79]. Its counter receptors
PDL-1/PDL-2 were found to be expressed on both antigen pre-
senting and tumor cells [81, 82].
Recently, it has been found that the PDL-1/PDL-2 signal-
ing pathway constitutes an important element of tumor immu-
nosuppression that is involved in T lymphocyte activation and
improvement in the immune tolerance of tumor cells, thereby
achieving tumor immune escape. Therefore, targeting the PD-
L1/PD-1 pathway is an attractive option for cancer treatment.
Table 2 Anti-cancer properties of CXCL10
Cancer Anti-cancer effect(s) Model Cell line(s) Ref.
Prostate Inhibits cell proliferation and reduces PSA production In vitro LNCaP [17]
Colon Inhibits angiogenesis In vivo, In vitro CT26 [16]
Lung Inhibits angiogenesis In vivo, In vitro LL/2 Lewis [16]
Gastric Inhibits angiogenesis and attracts anti-tumoral
T lymphocytes
In vitro – [18]
Cervical Inhibits tumor growth, decreases vessel density,
reduces cell proliferation and increases apoptosis
In vivo HeLa [19]
Brain Inhibits tumor neovascularization In vivo Gl261 [20]
Neonatal sepsis Improves macrophage and granulocyte function In vivo [76]
Hepatocellular Generates effector T cell trafficking In vivo Mouse hepatitis virus
(MHV) strain
[73]
Oral (tongue) – Human [74]
Ovarian Induces tumor-suppression by TIL recruitment In vitro OV-MZ-6/ SKOV-3 [75]
Breast Chemoattracts tumor-specific T cells, induces proliferation,
survival and functional activation of TILs
In vitro 4 T1 [60]
Colorectal Induces infiltration of GzmB+CD8+ cytotoxic
T lymphocytes (CTLs) and IFN-γ+CD4+ helper T cells
Human – [72]
Melanoma Inhibits angiogenesis and Treg cells and induces
apoptosis, activates T cells and increases survival rates
In vitro, In vivo B16F10 [40]
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As yet, however, the therapeutic effectiveness of PD-L1/PD-1
targeting has remained relatively poor [83]. Whereas effec-
tiveness of anti CTLA-4 mAb-based therapy has been report-
ed in approximately 20% of melanoma patients, more than
50% of patients yielded positive results after using a combi-
nation of anti PD-1 and anti CTLA-4 treatments [79, 84, 85].
Therefore, interest was raised to evaluate additional check-
point molecules that may exert therapeutic effects in different
types of cancer (particularly melanoma) independently or in
combination with anti PD-1 and/or anti CTLA-4 treatment
regimens. In this respect, the question has been raised whether
the CXCL10/CXCR3 axis is able to act as a new immune
checkpoint to be targeted for cancer immunotherapy. Various
studies have reported that conventional therapies can upregu-
late CXCL10 in the tumor microenvironment for the recruit-
ment of T cells directed against tumor cells (Table 3). By
inducing Granzyme B and effector Th1 cells, CXCL10 has
been found to be accompanied by the production of effector
Th1 cells and the recruitment of CXCR3+CD8+ T cells to the
tumor site, respectively, which could potentiate their anti-
tumor activities (Fig. 2) [72]. The ability of a stabilized form
of CXCL10 (CXCL10-Ig) to suppress myeloma has recently
been assessed. A marked reduction in myeloma development
through a decrease in the number of Treg cells and an elevated
accumulation of effector CD4+, CD8+ and NK cells at the
tumor site were reported after applying CXCL10-Ig to mice
engrafted with myeloma cells [86]. Dipeptidylpeptidase 4 in-
hibitors were used by Barreira da Silva et al. to increase en-
dogenous CXCL10 levels, which resulted in growth suppres-
sion of experimental melanomas [72]. The results were also
indicative of an enhanced anti-tumor activity during combina-
tion of CXCL10 augmentation with other immune checkpoint
therapies. Nevertheless, it is worth noting that there is a limi-
tation in the use of immune checkpoint therapies. An im-
proved immunity that is efficacious enough to efficiently
suppress cancer growth increases the risk for autoimmunity
mainly due to the fact that Treg cells serve as gatekeepers for
preventing autoimmunity [87–89]. Besides the studies men-
tioned, recent work has shown that therapeutic efficacy can be
enhanced by a combination of radiotherapy and CXCL10
therapy in cervical cancer (HeLa) cells in a murine xenograft
model [19]. In the cancer cells, the negative autocrine effect
could be mediated by CXCL10, in addition to its impact on
the immune system. Therefore, survival was enhanced in
tumor-bearing mice treated with CXCL10 [90]. Correlations
between elevated CXCL10 expression levels at the tumor site
and improved clinical prognoses have previously been report-
ed for different types of human cancer [9, 75, 91]. However,
more studies are needed to determine whether these patients
require a direct intra-tumor administration of the chemokine or
a personalized treatment of systemic administration of
CXCL10 in a stabilized form (assuming that anti-tumor Tcells
that are induced in the periphery will home at the tumor site).
In order to treat lung metastases in an immunocompe-
tent mouse model of metastatic melanoma (B16F10), we
have recently evaluated the potential of human adipose-
derived mesenchymal stem cells (hADMSC) genetically
engineered to express CXCL10 [92]. To this end, we
exploited a piggybac vector encoding CXCL10 for the
transfection of hADMSCs ex vivo. Ten days after tumor
cell inoculation, tumor-bearing mice were intravenously
administered with hADMSCs expressing CXCL10. After
another 10 days, one cohort was used to evaluate long-
term survival and another cohort (10 mice in each group)
was sacrificed to evaluate the treatment impacts. We
found that the growth of B16F10 melanoma cells was
inhibited and that the survival was considerably
prolonged by systemic injection of the hADMSCs ex-
pressing CXCL10. In addition, significant reductions in
angiogenesis and the frequency of Treg cells in the lungs
Table 3 Prospective approaches associated with CXCL10 for the treatment of melanoma
Therapy Effect(s) Model(s) Ref.
Anti-PD-1 Stimulates T cells and decreases tumor growth In vivo [100]
Anti-PD-1 does not decrease tumor growth In vivo [101]
Anti-CTLA4 Stimulates T cells In vivo, Human [102]
Anti-DPP4 Enhances responses to immunotherapy In vivo [103]
COX-inhibitor with anti- PD-1 Combination of celecoxib and anti-PD-1 stimulates
T cells and decreases Tregs and MDSCs,
which may lead to tumor growth inhibition
In vivo [104]
Dacarbazine, temozolomide, cisplatin Stimulates T cells and improves prognosis In vitro, In vivo [105]
ACT therapy CXCL10 expression in pretreated tumors is related
to therapy responsiveness
In vitro, In vivo [106]
Recombinant MAGE-A3 antigen CXCL10 expression in pretreated tumors is related
to therapy responsiveness
In vivo, Human [107]
ACT: Acceptance and Commitment Therapy; CTLA4: Cytotoxic T lymphocyte-associated protein 4; COX: Cyclooxygenase; DPP-4: Dipeptidyl
peptidase 4; MAGE-A3: Melanoma-associated antigen 3; PD-1: Programmed cell death-1
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were noted. Furthermore, we found that the trafficking of
activated T cells to the lungs and tumor cell apoptosis
increased considerably. Based on these results, we con-
cluded that an anti-tumor effect could be exerted on lung
metastasis of melanoma cells through the targeting of tu-
mor sites by hADMSCs expressing CXCL10 [92].
Immune recruitment by CXCL10/CXCR3 has been report-
ed by several investigators. To emphasize the fundamental
role of CXCL10/CXCR3 in immune cell migration, Chheda
et al. noted that CXCR3 knockout mice exhibited an overt
tumor growth and reduced survival using a syngeneic murine
B16 melanoma model. Moreover, it was found that anti-PD-1
therapy failed to shrink tumors in CXCR3-deficient mice
[101]. It has also been shown that blocking CXCL10 inhibits
CXCR3+CD8+ T cell recruitment leading to proliferation and
metastasis [93].
Fig. 2 Role of CXCL10 in directing the biological function and polarization of CD8+ and CD4+ Tcells. After generation at inflammation or tumor sites,
CXCL10 potentiates the effector activities of CD8+ and CD4+ T cells, which subsequently move directly to target sites to exert their effector activities
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Next to the immunomodulatory role of CXCL10, it may
serve as a biomarker for metastasis status [94] and for the
prediction of early metastatic recurrence [27]. The presence
of chemokines, particularly CXCL10, in cerebrospinal fluid of
melanoma patients could, for example, indicate the occur-
rence of brain metastasis [94]. In conformity with the ability
of CXCL10 to reduce tumor growth, it has been reported that
an adenovirus vector expressing human CXCL10 induced
35% reduction in tumor growth and reduced melanoma cell
invasion in vitro [15]. In addition, it has been found that
IFN-β can inhibit the proliferation/progression and metastasis
of melanoma cells via CXCL10. It has also been reported that
CXCR3-B down-regulation is associated with resistance to
IFN-β, underscoring the inhibitory role of CXCR3-B in mel-
anoma cells [95].
In addition, it has been found that microphthalmia-
associated transcription factor (MITF) knockdown reduces
CXCL10 expression and accelerates tumor outgrowth [96].
MITF, which is a key transcriptional regulator expressed in
80% of melanoma cells, leads to a poor survival. This obser-
vation may be related to the autocrine CXCL10/CXCR3 loop,
and heterogeneity or differences in chemokine expression pat-
terns between murine and human melanoma models.
D’Arcangelo et al. found that Platelet Derived Growth
Factor Receptor-alpha (PDGFR-α) can up-regulate CXCL10
up to 20-fold, and strikingly inhibit the proliferation of endo-
thelium and melanoma cells in a CXCL10-dependent manner
[97].
Results of several current melanoma therapeutic strategies
have indicated that CXCL10 represents one of the marked
elements of these strategies, being beneficial in pushing for-
ward the anti-cancer activities of common therapeutic strate-
gies. Concordantly, it has been shown that one of the enhanc-
ing elements of thalidomide is CXCL10 in melanoma therapy
[98]. Moreover, treatment with all-trans retinoic acid (ATRA)
and polyinosinic: polycytidylic acid (polyI:C) has been found
to result in higher mRNA and secreted CXCL10 levels [99].
Additional experimental and clinical studies are required to
substantiate the pivotal role of CXCL10 in the pathophysiol-
ogy of melanomas and its application to the targeted therapy
of melanomas. Combination of this chemokine with routine
conventional treatments may reduce their adverse effects, im-
prove the quality of life and increase the overall survival of
affected melanoma patients.
6 Conclusions and perspectives
The double-edged sword of the CXCL10/CXCR3 axis in its
anti- and pro-tumorigenic properties is primarily related to the
heterogeneity among cancers, the occurrence of CXCR3 iso-
forms, as well as the presence of paracrine/autocrine loops in
different tissues and cells. In melanoma, the paracrine
CXCL10/CXCR3 loop is proposed to be strongly associated
with anti-cancer properties. On the other hand, the autocrine
loop appears to be correlated with tumor initiation and pro-
gression. Recently, CXCL10 has been proposed as a potential
therapeutic target in melanoma. It should, however, be taken
into consideration that CXCL10 may have either beneficial or
disadvantageous effects in different patients. Moreover,
higher CXCL10 levels may result in adverse effects in some
tissues such as cancer tissues. As described above, using
CXCL10 as a single melanoma therapy may not be very effi-
cacious, whereas combinations of CXCL10 with other thera-
peutic strategies may form a rationale for achieving better
therapeutic options for melanoma patients.
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